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Abstract: More than 50% of people with dementia experience behavioral and psychological 
symptoms of dementia (BPSD). BPSD are distressing for patients and their caregivers, and are 
often the reason for placement into residential care. The development of BPSD is associated 
with a more rapid rate of cognitive decline, greater impairment in activities of daily living, and 
diminished quality of life (QOL). Evaluation of BPSD includes a thorough diagnostic investiga-
tion, consideration of the etiology of the dementia, and the exclusion of other causes, such as 
drug-induced delirium, pain, or infection. Care of patients with BPSD involves psychosocial 
treatments for both the patient and family. BPSD may respond to those environmental and 
psychosocial interventions, however, drug therapy is often required for more severe presentations. 
There are multiple classes of drugs used for BPSD, including antipsychotics, anticonvulsants, 
antidepressants, anxiolytics, cholinesterase inhibitors and NMDA modulators, but the evidence 
base for pharmacological management is poor, there is no clear standard of care, and treatment 
is often based on local pharmacotherapy customs. Clinicians should discuss the potential risks 
and beneﬁ  ts of treatment with patients and their surrogate decision makers, and must ensure a 
balance between side effects and tolerability compared with clinical beneﬁ  t and QOL.
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Typical behavioral and psychological symptoms 
of dementia
Eighty to 94% of residents of long term care facilities have a major psychiatric ill-
ness. Dementia is the most prevalent, observed in 47%–78% of residents (Rovner 
et al 1990; DeVane and Mintzer 2003). Regardless of its etiology, dementia is a 
clinical syndrome that expresses itself in three areas: cognitive deﬁ  cits, psychiatric 
and behavioral disturbances, and difﬁ  culties in carrying out daily functions (De Dyn 
et al 2005). Alois Alzheimer, in his 1906 description of dementia, noted behavioral 
and psychological symptoms of dementia (BPSD) are prominent manifestations of the 
illness, including paranoia, delusions of sexual abuse, hallucinations and screaming 
(Kozman et al 2006). In 1996, the International Psychogeriatric Association convened 
a consensus conference on the behavioral disturbances in dementia. The consensus 
group made this statement: “The term behavioral disturbances should be replaced by 
the term BPSD, deﬁ  ned as symptoms of disturbed perception, thought content, mood 
or behavior that frequently occur in patients with dementia (Kozman et al 2006, p 1).” 
BPSD is not a diagnostic entity but is instead a term that describes a clinical dimension 
of dementia (Lawlor 2004). The multiple cognitive impairments of dementia are often 
associated with mood disorders and sleep disturbances. BPSD includes disinhibited 
behavior, delusions and hallucinations, verbal and physical aggression, agitation, 
anxiety and depression (Carson et al 2006). BPSD can cause tremendous distress for 
both the patient and the caregiver, and is often the trigger for referral of these patients 
to primary care and specialist services and placement in residential or nursing home Clinical Interventions in Aging 2007:2(4) 612
Hersch and Falzgraf
care (Steele et al 1990; Ballard et al 2006). The development 
of BPSD is also associated with a poorer prognosis, a more 
rapid rate of cognitive decline, illness progression (Stern et al 
1987; Paulsen et al 2000), greater impairment in activities 
of daily living (ADLs) (Lyketsos et al 1997) and diminished 
quality of life (QOL) (Gonzales-Salvador et al 2000), and 
it adds signiﬁ  cantly to the direct and indirect costs of care 
(O’Brien and Caro 2001).
At least half of patients attending outpatient dementia 
clinics, and more than 75% of patients in nursing homes 
have some sort of BPSD (Zaudig 2000). The prevalence of 
BPSD in these 24 hour care settings has been reported to be 
as high as 90%, with individual behaviors including delusions 
(20%–73%), depression (up to 80%), and aggression and 
hostility (20%–50%). As many as 80% of Alzheimer’s 
dementia (AD) patients will develop symptoms of BPSD 
during the course of their illness, often with the onset of 
cognitive impairment (Lyketsos et al 2002). Patients with 
mixed AD and vascular dementia have the highest level of 
psychiatric disturbances (Zaudig 2000; Kindermann et al 
2002; Kozman et al 2006).
While the origin of BPSD remains unclear; it is presumed 
there are multiple etiologies for these symptoms. There 
are neurobiological, psychological (premorbid personality 
features and responses to stress), and social (environmental 
change and caregiver factors) aspects (Zaudig 2000). The 
neurobiology of behavioral disturbances involves correlations 
between memory deﬁ  cits and decreasing cholinergic function, 
and between serotonin and noradrenaline depletion and a his-
tory of depression or aggression. Dysregulations in GABA 
(gamma-aminobutyrate)-ergic, serotonergic and noradrener-
gic neurotransmitter systems that have been associated with 
increased aggressiveness and disturbances are also found in 
dementia patients (Eichelman 1987; Stoppe et al 1999).
BPSD are now accepted as an important therapeutic target 
in dementia. Mild forms of BPSD may respond to simple 
environmental and psychosocial interventions. Although 
non-pharmacologic interventions should be the ﬁ  rst line of 
treatment, drug therapy is often required for the more severe 
psychotic, aggressive, and agitated presentations (Lawlor 
2004; Sink et al 2005).
Methods of measuring BPSD 
and the associated challenges
It is important to remember that behavior is merely a form of 
communication (Kozman et al 2006). BPSD can be difﬁ  cult 
to diagnose, given the variety of symptoms. Evaluation of 
BPSD includes a thorough diagnostic investigation, careful 
consideration of the etiology of the dementia, and the 
exclusion of other causes, such as drug-induced delirium or 
adverse effects of treatments for comorbid conditions (Finkel 
et al 1996; Zaudig 2000). Undiagnosed medical problems 
such as pain, depression, dehydration, sleeping difﬁ  culty, 
anxiety and delirium can all lead to agitation.
Pain is often underdiagnosed in patients with demen-
tia, and can manifest itself by behavior changes (such as 
agitation and increased confusion) and decreased mobility 
(Pautex et al 2006). Language difﬁ  culties associated with 
dementia interfere with the patient’s ability to express pain. 
In addition, the autonomic activation in response to pain may 
be blunted in AD patients. A number of pain scales have 
been developed to evaluate pain in patients with dementia. 
Some are self-report (for milder dementia); others, such 
as the PAIN-AD-Pain Assessment in Advanced Dementia 
(Lane 2003), measure non-verbal signs such as breathing, 
vocalization, facial expression, and body language. A small 
study (Douzjian 1998) found that empiric pain medication 
reduced troublesome behaviors, and allowed for a reduction 
in psychoactive medication. Positioning and physical therapy 
may able be helpful.
Sleep disturbances may be associated with and part of 
BPSD. Circadian rhythms may be altered in AD. Patients 
with Lewy Body dementia have a high incidence of REM 
sleep disorders, acting out their dreams. Clinicians should 
evaluate medications that may disrupt sleep. Other common 
medical causes of confusion and agitation in the elderly 
include infections, endocrine disorders, ﬂ  uid and electrolyte 
imbalances, and constipation (Daniel 2000). Emotional and 
interpersonal issues (such as dislike for certain foods or 
reactions of other people to the patient’s behavior) can be a 
signiﬁ  cant factor in agitation. Environmental factors, such as 
enclosed spaces, isolation, and visual and auditory sensory 
deprivation may all contribute to or cause a problem.
The diagnostic evaluation and treatment of BPSD 
require special considerations. Institutionalized, demented 
and acutely ill elders, particularly those taking multiple 
medications, are at risk for BPSD. The aging brain provides 
a different substrate for both the therapeutic and potentially 
toxic effects of medications. In elderly patients with degen-
erative brain disorders, the normal redundancy, interdepen-
dence, and checks and balances of neuronal networks and 
neurotransmitters may be disturbed or deﬁ  cient. For example, 
delirium may be reversible if the underlying medical causes 
are addressed promptly, or fatal if overlooked or untreated. 
A careful medication review should be performed, paying 
particular attention to any recently introduced medications. Clinical Interventions in Aging 2007:2(4) 613
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Elderly patients may be more vulnerable to the cognitive 
effects of drug interactions or to what may be considered 
therapeutic blood drug levels in younger patients (Stoppe 
et al 1999; Daniel 2000). Many medications can cause 
delirium or dementia-like symptoms (Tariot, Profenno et al 
2004). While drugs with anticholinergic properties are often 
associated with delirium or behavior changes, many others 
such as psychoactive and cardiovascular drugs may also be 
implicated.
More than 30 scales are available for measuring the 
behavioral manifestations of dementia (Weiner et al 1996; 
Stoppe 1999). A number of instruments have been developed 
to assess the range and severity of BPSD (see Table 1). The 
most useful, in terms of outcomes assessment, are the Cohen-
Mansﬁ  eld Agitation Inventory (CMAI), neuropsychiatric 
inventory: nursing home version (NPI-NH), and behavioral 
pathology in AD (BEHAVE-AD) scales. They are particu-
larly useful because of their speciﬁ  city, reliability and validity 
in BPSD (Zaudig 2000; De Deyn et al 2001). It is not clear 
how much of a percentage change in each assessment tool 
represents a clinically signiﬁ  cant response, however (Lee 
et al 2004).
Recognition of BPSD is the ﬁ  rst step in developing a 
management plan, and care must be taken to establish its 
presence. The goal of treatment should be to detect and 
manage BPSD before caregiver burnout and irreversible 
damage to the support environment occurs. The plan should 
consider the severity and intrusiveness of the behavior and 
whether non-pharmacologic intervention is sufﬁ  cient or the 
behavior is signiﬁ  cant enough to require both pharmacologic 
and psychological interventions (Lawlor 2004). Identify-
ing target syndromes (such as psychotic syndrome versus 
psychomotor agitation or a sleep disturbance) is useful in 
development of the management plan. Useful clinical out-
comes such as nursing home placement, QOL, and caregiver 
burden improve a clinician’s ability to interpret test results 
and inform patients and families about the risks and beneﬁ  ts 
of treatment (Sink et al 2005).
Non-pharmacologic therapy 
and its evidence
Care of patients with BPSD involves a broad range of psycho-
social treatments for both the patient and family. Caregiver 
education, support and behavioral training are integral parts 
of the intervention for these patients (Lawlor 2004; Sink et al 
2005). Interventions need to be approached in a systematic 
manner that includes management of the patient’s physical 
health, psychiatric symptoms, and environmental factors 
(Kozman et al 2006). In a study by Palmer et al (1999), the 
use of hearing aids improved scores on the BEHAVE-AD. 
Environmental adjustments, such as lifestyle support are 
generally ﬁ  rst line interventions; however, many cases of 
aggression, agitation and psychotic symptoms may require 
pharmacotherapy (Zaudig 2000).
Individualized music therapy, bright light treatment (BLT) 
and aromatherapy have been found to improve certain prob-
lematic behavioral symptoms (Lawlor 2004), as has pet therapy 
(Sink et al 2005). In a randomized controlled trial (RCT) by 
Smallwood et al (2000), a combination of aromatherapy and 
massage mid-afternoon resulted in a reduction in the fre-
quency of behavioral disturbances. In a larger, double-blind, 
placebo-controlled trial, aromatherapy was found to be a safe 
and effective treatment for clinically signiﬁ  cant agitation in 
patients with severe dementia (Ballard et al 2002). Lovell 
et al (1995) studied the effect of BLT on levels of agitation 
in moderately to severely demented persons. Agitation scores 
were signiﬁ  cantly reduced during therapy compared with 
controls (Lovell et al 1995). Good sleep hygiene, avoidance of 
Table 1 Common scales used for measuring the behavioral 
manifestations of dementia
Test name  Test description
Cohen-Mansﬁ  eld  Developed in 1986.  It examines 29
Agitation Inventory  types of agitated behavior, including
(CMAI)  pacing, verbal or physical aggression, 
  repetitious mannerisms, screaming and
 general  restlessness.a
Neuropsychiatric Inventory:  Assesses 12 behavioral disturbances:
Nursing Home  delusions, hallucinations, agitation,
version (NPI-NH)  dysphoria, anxiety, apathy, irritability,
  euphoria, disinhibition, aberrant
  motor behavior, nighttime behavior
  disturbances and appetite and eating  
 abnormalities.b
Behavioral Pathology in   Developed in 1987.  It is a structured 
AD (BEHAVE-AD)  psychiatric interview, assessing
  25 behaviors in 7 areas: paranoid and 
  delusional ideation, hallucinations,
  activity disturbances, aggressiveness,
  diurnal rhythm disturbances,
  affective disturbance and
  anxieties and phobia.c
Clinical Global Impression  Establishes a global rating of all aspects
of Change (CGI-C)  of the patient’s condition.
Functional Assessment  Measures the levels of basic activities
Staging scale (FAST)  such as bathing and toileting, and
  rates patients from independent
  to totally dependent.
aBallard et al 2006; Kozman et al 2006.
bCarson et al 2006.
cCarson et al 2006; Kozman et al 2006.Clinical Interventions in Aging 2007:2(4) 614
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caffeine and alcohol, and adequate daytime physical activity 
can be beneﬁ  cial, particularly for patients who have sleep 
disturbances and depression. In a randomized controlled trial 
by Teri et al (2003), a combination of exercise training and 
caregiver education on behavioral management techniques 
resulted in improvements in depression and a trend toward 
less institutionalization. Teaching caregivers techniques to 
minimize behavior problems can make the home environ-
ment less stressful for both the family and the patient (see 
Table 2). Sloane et al (2004) performed an RCT which mea-
sured agitation and aggression, comparing usual hygiene with 
person-centered showering and towel baths. Results showed 
that the latter techniques were effective methods of reducing 
BPSD during bathing persons with dementia. Finally, physi-
cal restraints should be avoided, for they are associated with 
injury, not protection, of confused or demented patients (Miles 
et al 1992; Sink et al 2005).
Pharmacologic management 
and its evidence
The evidence base for drug treatment of the behavioral and 
psychological symptoms of dementia is poor, considering the 
size of the problem and the distress these symptoms cause. 
Over the years, drug prescribing for BPSD has evolved in a 
haphazard and anecdotal way. Although there are multiple 
classes of drugs in use for neuropsychological symptoms, 
including antipsychotics, anticonvulsants, antidepressants, 
anxiolytics, cholinesterase inhibitors and NMDA modula-
tors, there is no consensus nor clear standard of care, and 
treatment is often based on local pharmacotherapy customs 
(Sink et al 2005). A balance needs to be made between side 
effects and tolerability and safety issues compared with clini-
cal beneﬁ  t and QOL (Kozman et al 2006). In elderly patients, 
it is possible that any medication could help and/or harm, 
and the safety of a drug must be considered in the context 
of its known efﬁ  cacy (Schneider et al 2005).
Since the neurobiology of BPSD is still unclear, it 
seems likely that the symptoms may involve different 
neurotransmitter systems and may therefore respond to 
different therapies (Kozman et al 2006). Drug-responsive 
symptoms include anxiety, verbal and physical agitation, 
hallucinations, delusions, and hostility, whereas wandering, 
hoarding, unsociability, poor self-care, screaming and other 
stereotypical behavior seem to be unresponsive to all drugs 
(Maletta 1990; Stoppe et al 1999). Pharmacologic interven-
tion is often necessary and includes use of antidepressants for 
mood disorders, anticonvulsants for nonpsychotic agitation 
and antipsychotics for aggression, agitation and psychotic 
symptoms. Antidepressants, anxiolytics and hypnotics should 
only be used in patients with marked and persistent symptoms 
and drug treatment should be targeted to speciﬁ  c syndromes 
that are clinically signiﬁ  cant because of their frequency, 
pervasiveness, or impact (Lawlor 2004).
If drug therapy is to be instituted, Sink et al (2005) 
recommend two approaches to the management. One is to 
identify the target symptom and choose a drug that is known 
to treat symptoms most closely related to the one the patient 
is exhibiting (as mentioned above). An alternative approach is 
one guided by current evidence in combination with the goal 
of minimizing side effects. They recommend beginning with 
a cholinesterase inhibitor if the patient is not already on one, 
because they are well tolerated and may beneﬁ  t cognition and 
function. It is important to remember that titration speed and 
target dosage of psychoactive drugs are substantially reduced 
in the elderly (Daniel 2000). Benzodiazepines should be 
avoided, especially for long term management, as their use 
can lead to increased confusion, falls and may paradoxically 
increase agitation in patients with dementia. No psychoactive 
medication prescribed to treat neuropsychiatric symptoms of 
dementia should be continued indeﬁ  nitely and attempts at 
Table 2 Behavioral management interventions
Activity associated  Intervention
with potential BPSD
Bathing  Make a safe bathroom. Be prepared, don’t 
  rush. Ensure room and water temperature 
  are comfortable. Wash hair last. A recent 
  study found beneﬁ  t of person-centered 
  bathing and towel bath in decreasing 
  agitation and discomfort.a
Dressing  Limit choices. Prepare clothing. Give 
 speciﬁ  c cues.  Provider larger clothing and 
  soft stretchy fabrics. Provide duplicate 
 outﬁ  ts and comfortable shoes with Velcro.
 Give  positive  reinforcement.
Eating  Maintain a regular mealtime. Avoid 
  distraction at meals. Check the food 
  temperature. Honor preferences when 
  possible, and offer ﬁ  nger foods.
Wandering  Provide adequate daily physical activity.
  Create a safe environment and safe 
  wandering paths. Remove reminders of 
  leaving (coats, umbrella). Have alarms or 
  bells at exit doors. ID bracelet and “Safe 
  Return” programs are available.
Incontinence  Scheduled voiding.  Be attentive to 
  nonverbal cues (such as pacing). Simplify 
  clothing and clear obstacles. Put signs 
  (including pictures) at the bathroom door.
 Give  positive  reinforcement.
aSloane et al 2004.Clinical Interventions in Aging 2007:2(4) 615
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drug withdrawal should be made regularly. Because of the 
instability of the symptoms of BPSD, many patients who are 
prescribed antipsychotics for neuropsychiatric symptoms 
will no longer need them when the drug is later discontinued 
(Stoppe et al 1999).
Medications commonly 
used to treat BPSD
In psychotic, behaviorally disturbed elders, an ideal medication 
should have rapid onset, sustained action and minimal somatic 
and cognitive side effects (Daniel 2000). Conventional anti-
psychotics, such as haloperidol, have been used effectively to 
control the behavioral and psychological symptoms of demen-
tia. Other drugs, such as valproate and carbamazepine, have 
shown some efﬁ  cacy in controlling behavioral symptoms in 
elderly patients (Mellow et al 1993; Tariot et al 1994; DeVane 
and Mintzer 2003). However, only the atypical antipsychotics 
risperidone and olanzapine currently have the best evidence 
of efﬁ  cacy in treating neuropsychiatric symptoms. Trials of 
cholinesterase inhibitors have had consistent yet small positive 
effects as well (Sink et al 2005).
Antipsychotics
Antipsychotic medications have been the mainstay of psycho-
pharmacological treatment for BPSD during the last several 
decades despite their overuse in the 1980s and the federal 
regulations implemented in the early 1990s (Schneider et al 
2005). Up until the mid 1990s, conventional neuroleptics 
such as haloperidol were the primary pharmacologic treat-
ments for BPSD. Antipsychotics are the drugs of choice 
in the treatment of intrusive delusions and hallucinations. 
Coexisting nonpsychotic symptoms including sleeplessness, 
excitability, hostility, belligerence, emotional liability, rest-
lessness, agitation, aggression and irritability may also show 
improvement with antipsychotics. Other symptoms such 
as hypersexuality, apathy and withdrawal do not generally 
improve. Since antipsychotics have such a narrow therapeutic 
window, they should be prescribed and dosage adjusted with 
the expectation of clinical improvement within a certain 
timeframe (Kindermann et al 2002). If improvement is not 
observed, the medication could be discontinued or switched 
after two to four weeks (Schneider et al 2005; Schneider, 
Tariot et al 2006). Low dosages and careful dose titration are 
needed when prescribing them to the elderly with dementia. 
However, these low dosages may also lead to limited efﬁ  cacy 
(Stoppe et al 1999).
In the past, antipsychotic use in dementia has been 
excessive, possibly inappropriate, and poorly monitored. 
The goal of antipsychotic therapy must be the improvement 
in a speciﬁ  c target behavioral syndrome without impairing 
other aspect of dementia such as cognition, function, and 
quality of life (Lawlor 2004). Antipsychotics are more 
effective than placebo, but the effect is modest and they 
are frequently associated with adverse effects, includ-
ing increased risk of falls and drowsiness, parkinsonism, 
akathisia, tardive dyskinesa (TD), social withdrawal, 
accelerated cognitive decline, QT prolongation, stroke, and 
sensitivity reactions (Ballard et al 2006). Both conventional 
antipsychotics and just the presence of psychosis have been 
associated with more rapid cognitive decline in dementia 
patients (Schneider, Dagerman et al 2006). Patients with 
Lewy Body dementia have been reported to have marked 
sensitivity, including neuroleptic malignant syndrome, to 
typical and atypical antipsychotics, especially risperidone 
(Ballard et al 1998; Sink et al 2005).
The newer atypical antipsychotics are associated with 
fewer extrapyramidal symptoms (EPS) (Jeste et al 1999; De 
Dyn et al 2005). The perceived safety advantages of the atypi-
cals include less of the following: sedation, cardiovascular 
(CV) adverse effects, postural instability, falls and movement 
disorders. The FDA added warnings of increased CV adverse 
events to the US prescribing information for some atypical 
antipsychotics in April 2003, January 2004 and February 
2005. In April 2005, the FDA issued a health advisory for 
increased risk for death with use of atypicals in patients with 
dementia (Kozman 2006; Schneider, Dagerman et al 2006).
Atypical antipsychotics
The American Academy of Neurology recommends the use 
of antipsychotics to treat agitation and psychosis in patients 
with dementia where environmental manipulation fails, and 
guidelines state that atypical antipsychotics may be better 
tolerated than older conventional antipsychotics (Doody 
et al 2001; Carson et al 2006). Clozapine, the prototypical 
atypical antipsychotic, was approved in 1989. Since then, 
risperidone, olanzapine, quetiapine, ziprasidone and aripip-
razole have been introduced (Carson et al 2006). Risperidone 
was the ﬁ  rst agent to be proven effective for the behavioral 
and psychological diagnoses of dementia, and it has the 
largest database of double-blind controlled trials to support 
its efﬁ  cacy (De Dyn et al 2005). It is effective in controlling 
aggression, agitation and psychotic symptoms in patients 
with many different forms of dementia. It is well tolerated and 
does not further impair the daily function of elderly patients 
with dementia (Zaudig 2000). Atypical antipsychotic drugs 
in general are widely used to treat psychosis, aggression and Clinical Interventions in Aging 2007:2(4) 616
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agitation in patients with AD, however, their beneﬁ  ts are 
uncertain and concerns about safety have emerged.
In a double-blind, placebo-controlled trial (Schneider, 
Tariot et al 2006), 421 outpatients with AD and psychosis, 
aggression or agitation were randomly assigned to receive 
risperidone, olanzapine, quetiapine, or placebo. No signiﬁ  -
cant differences were noted with regard to improvement on 
the CGIC scale. Adverse effects offset advantages in the 
efﬁ  cacy of atypicals for the treatment of BPSD (Schneider, 
Tariot et al 2006). A 2006 Cochrane Review (Ballard et al 
2006) evaluated 16 placebo-controlled studies with atypicals. 
Only 9 had sufﬁ  cient data for a meta-analysis. The review 
looked at outpatients or people living in care facilities and 
found (Ballard et al 2006, p 5):
1. A  signiﬁ  cant improvement in aggression with risperidone 
and olanzapine compared to placebo.
2. A significant improvement in psychosis with 
risperidone.
3.  Risperidone and olanzapine patients had a signiﬁ  cantly 
higher incidence of serious adverse CV events and 
EPS (especially with risperidone doses greater than 
1 milligram).
4. A  signiﬁ  cant increase in drop-outs with risperidone and 
olanzapine.
5.  Data was insufficient to comment on cognitive 
function.
These reviewers and numerous other studies throughout 
the literature have come to similar conclusions that, over-
all, the evidence for olanzapine and risperidone supports 
their efﬁ  cacy compared with placebo, but their potential 
for increased risk of CV events and mortality is a serious 
concern and limits their overall effectiveness (Ballard et al 
2006; Carson et al 2006; Schneider, Tariot et al 2006). Like-
wise, the Committee on the Safety of Medications reported 
a three-fold increase in the risk of CV adverse events with 
the atypicals, compared with placebo. Both olanzapine and 
risperidone have good evidence base and they appear to be 
well tolerated otherwise. Considering the consistency of the 
risks among the various studies reviewed, it is likely that 
there is increased risk from any of the atypicals and not from 
a particular one (Schneider et al 2005). The modest efﬁ  cacy 
and uncertain response rates combined with the risks detailed 
suggest that antipsychotics should be used within the context 
of medical need and the efﬁ  cacy and safety of alternatives 
(Schneider, Dagerman et al 2006). Their use should be 
targeted towards the treatment of those patients in whom 
BPSD are prominent and associated with signiﬁ  cant distress, 
functional impairment or danger to the patient (De Dyn et al 
2005). The use of lower doses might be prudent and effective 
(Schneider, Dagerman et al 2006).
The adverse effects associated with atypical antipsychotics 
seem to be dose related, supporting the practice of starting 
with a low dose and increasing slowly as the drug is tolerated. 
In addition to the adverse CV effects discussed above, there is 
increasing evidence that the treatment with antipsychotics may 
be associated with metabolic disturbances such as impaired 
glucose metabolism, hyperlipidemia, and weight gain, all 
of which may adversely affect QOL (Lee et al 2004; Jones 
et al 2006). Neutropenia and agranulocytosis may also occur 
with olanzapine (Benedetti et al 1999; Zaudig 2000). There 
were no clinically relevant changes in blood pressure or heart 
rate in phase III studies with risperidone, nor were there any 
occurrences of EKG abnormalities (Katz et al 1999; Zaudig 
2000). There has been no evidence for increased injury, fall 
or syncope; however the risks of somnolence and urinary tract 
infections (or incontinence) are increased with the atypicals 
(Schneider, Dagerman et al 2006). Sedation is particularly 
likely with olanzapine, which can also be associated with 
increased confusion (Schneider, Tariot et al 2006).
Conventional antipsychotics
Conventional (or typical) antipsychotics have been exten-
sively studied in elderly demented patients with disappointing 
results. Effect size and response rates have been modest, with 
no consistent evidence that any conventional antipsychotic 
is more effective than another. Potentially serious adverse 
effects occur frequently, especially motor side effects, 
sedation, cognitive impairment, orthostatic hypotension, 
constipation, and urinary hesitancy (Daniel 2000; Lee et al 
2004). In the US, concerns about overuse of antipsychotics 
led to the introduction of legislation (the Omnibus Budget 
Reconciliation Act of 1987) that attempted to restrict pre-
scribing of antipsychotics to residents of nursing homes 
(Streim 1995; Stoppe et al 1999). Before the introduction of 
this act, up to 55% of nursing home residents were treated 
with antipsychotics (Lee et al 2004).
Haloperidol is the most widely studied typical antipsy-
chotic and modest improvement in psychosis and agitation has 
been reported in investigations with it (Kindermann et al 2002). 
A Cochrane review of haloperidol compared with placebo con-
cluded that haloperidol had no effect on agitation, behavioral 
symptoms as a whole, or CGIC scores, but appeared to reduce 
aggression (Sink et al 2005; Kozman et al 2006). In two other 
meta-analyses there was no difference in efﬁ  cacy among the 
different typical antipsychotics on neuropsychiatric symptoms 
(these studies included haloperidol, thioridazine, thiothixene, Clinical Interventions in Aging 2007:2(4) 617
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chlorpromazine, triﬂ  uoperazine and acetophenazine). There is 
no evidence that any one typical antipsychotic is more effec-
tive than another (Sink et al 2005). In addition, conventional 
antipsychotics were associated with a signiﬁ  cantly higher 
adjusted risk of death than were atypicals in all subgroups 
deﬁ  ned according to the presence or absence of dementia 
or nursing home residency (Wang et al 2005). The greatest 
increases in risk occurred soon after therapy was initiated 
and with higher dosages. Conventional antipsychotics are at 
least as likely as atypicals to increase the risk of death among 
elderly persons and should not be used to replace the atypicals 
that were discontinued in response to the 2005 FDA warning 
(Wang et al 2005).
Elderly patients are sensitive to EPS, especially parkin-
sonism, akathisia, and TD. Only one third of patients with 
dementia show behavioral improvement with conventional 
antipsychotic treatment, while the majority of patients treated 
with these will experience side effects, especially the anticho-
linergic effects (Tariot, Profenno et al 2004). The presence 
of EPS can lead to medication intolerance, falls and other 
adverse effects. In addition, typical antipsychotics have seri-
ous, potentially fatal, consequences in patients with Lewy 
Body dementia (Ballard et al 1998; Zaudig 2000). In one 
study, patients started on very low dosages of haloperidol or 
thioridazine developed parkinsonism within nine months of 
antipsychotic therapy (Kindermann et al 2002). The lower 
incidence of EPS and TD seen with atypicals represents a 
signiﬁ  cant beneﬁ  t to patients. Choosing antipsychotic agents 
with fewer anticholinergic properties is an important consid-
eration in elderly patients.
Anticonvulsants
Anecdotal reports have suggested that anticonvulsants such 
as carbamazepine, valproic acid and gabapentin may be 
effective in the treatment of BPSD. Gabapentin has shown 
some beneﬁ  t when treating aggressive behavior in patients 
with dementia, but it has not been well studied (Hawkins 
et al 2000; Kozman et al 2006). Carbamazepine has been 
investigated in several trials and was found to reduce agita-
tion, restlessness and anxiety (Tariot et al 1994; Stoppe et al 
1999), however the efﬁ  cacy and tolerability of long term use 
of this drug is yet to be established (Kozman et al 2006). 
Ataxia can occur in elderly patients treated with carbamaze-
pine (Kindermann et al 2002) and in the United States there 
is an FDA “black box” warning for hematologic toxicity 
and the potential for drug-drug interaction with its use (Sink 
et al 2005). Valproic acid had been reported to show some 
positive effects, with a benign adverse effect proﬁ  le (Mellow 
et al 1993; Stoppe et al 1999); however, in more recent 
studies it does not appear to be effective for the treatment 
of neuropsychiatric symptoms of dementia, whether in short 
or long acting preparations. It also caused signiﬁ  cantly more 
adverse effects than placebo, especially sedation. Therefore, 
valproic acid is not routinely recommended for the treatment 
of BPSD (Sink et al 2005).
Antidepressants
Depression is common in patients with dementia. As many 
as 40% of patients with dementia have signiﬁ  cant depres-
sive symptoms at some stage. Reducing symptoms such as 
irritability may aid in the treatment of BPSD (Kozman et al 
2006). Biochemical data have suggested that serotonergic 
deﬁ  cits in AD contribute to aggressive verbal and physi-
cal outbursts, sleep disturbance, depression and psychosis 
(Polluck et al 2002). Some antidepressants have signiﬁ  cant 
side effects, and not all studies have shown efﬁ  cacy in treat-
ment of neuropsychiatric symptoms of dementia other than 
depression (Sink et al 2005; Kozman et al 2006).
Selective serotonin reuptake inhibitors (SSRI’s) may have 
“neuroleptic” effects by reducing dopaminergic outﬂ  ow, and 
dysregulation in serotonergic neurotransmission may play 
an important role in the psychotic symptoms of dementia 
patients (Polluck et al 2002). Citalopram is the most selec-
tive, with moderate potency and high bioavailability. An 
open pilot study using citalopram demonstrated that it was 
well tolerated and the patients experienced a signiﬁ  cant 
reduction in agitation, hostility and suspicion (Polluck 
et al 1997). One review found that citalopram signiﬁ  cantly 
improved emotional bluntness, confusion, irritability, anxi-
ety, fear, depressed mood, and restlessness (Nyth et al 1990; 
Kozman et al 2006). In AD patients, psychotic and nonpsy-
chotic behavioral disturbances improved acutely with both 
citalopram and perphenazine. However, only citalopram 
demonstrated acute efﬁ  cacy superior to placebo (Polluck 
et al 2002). Sertraline, in conjunction with donepezil, showed 
statistically signiﬁ  cant improvement in CGIC scores (Finkel 
et al 2004; Kozman et al 2006), but in another trial, there 
was no signiﬁ  cant beneﬁ  t of sertraline on neuropsychiatric 
symptoms other than depression (Lyketsos et al 2003; Sink 
et al 2005). Trazodone is widely used for agitation, sleep 
disorders, and disruptive behavior because of its sedative 
effect and negligible anticholinergic activity. A comparison 
of trazodone with haloperidol for treatment of agitation in 
28 patients with dementia showed similar overall efﬁ  cacy of 
both drugs and a lower rate of adverse effects in the trazodone 
group (Sultzer et al 1997; Stoppe et al 1999).Clinical Interventions in Aging 2007:2(4) 618
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Cholinesterase inhibitors
Cholinesterase inhibitors are licensed for the treatment of 
mild to moderate AD (Kozman et al 2006). In some studies, 
donepezil had no effect on neuropsychiatric symptoms while 
in one study, anxiety, depression/dysphoria and apathy were 
signiﬁ  cantly improved compared with placebo (Feldman 
et al 2001; Kozman et al 2006). In Lewy Body dementia, 
donepezil has shown signiﬁ  cant improvement over time in 
behavioral symptoms (Lanctot and Herrmann 2000; Kozman 
et al 2006). Galantamine has demonstrated effectiveness, and 
has shown a signiﬁ  cant reduction in behavioral disturbances 
and improvement in the total NPI caregiver burden. A study 
using rivastigmine showed that long term therapy with it 
can slow the progression of BPSD symptoms, including 
aggressiveness and activity disturbances (Rosler et al 1999; 
Kozman et al 2006). In another study, rivastigmine signiﬁ  -
cantly improved neuropsychiatric and behavioral symptoms 
compared with baseline (Aupperle et al 2004; Kozman et al 
2006). Although some of these trials have shown statistically 
signiﬁ  cant differences, most data reporting the beneﬁ  ts on 
behavioral and psychological disturbances are from second-
ary outcome measures and the magnitude of effect has been 
small and of questionable clinical signiﬁ  cance (Sink et al 
2005). Further research is needed.
Other medications
Medications such as memantine, buspirone, beta blockers, 
benzodiazepines, and thiothixene (Finkel et al 1995) have 
been evaluated for their use in treating BPSD. Adding 
memantine to donepezil resulted in better outcomes (than 
placebo) for dementia patients on measures of cognition, 
ADLs, global outcome, and behavior. It showed a signiﬁ  -
cantly beneﬁ  cial effect compared with placebo in relation to 
agitation and aggression (Tariot, Farlow et al 2004; Kozman 
et al 2006). However, there does not appear to be a clini-
cally signiﬁ  cant beneﬁ  t using memantine in the treatment 
of neuropsychiatric symptoms of patients with moderate to 
severe AD (Sink et al 2005). A case report noted the addition 
of buspirone to antidepressants and olanzapine after 2 weeks 
resulted in signiﬁ  cant improvements (Cooper 2003; Kozman 
et al 2006). Its benign adverse effect proﬁ  le also makes 
buspirone a useful alternative in mild agitation. However, 
it showed less effect on agitation compared with trazodone 
or placebo (Lawlor et al 1994; Stoppe et al 1999). Low dose 
propranolol was effective in reducing disruptive, aggressive 
behavior in the majority of outpatients in one study; however, 
there are no controlled trials on use of beta blockers in BPSD 
(Shankle et al 1995; Kozman et al 2006). Benzodiazepines 
show signiﬁ  cantly more improvement in BPSD symptoms 
when compared with placebo; however, they should be used 
with caution because of their adverse effects (Stoppe et al 
1999; Zaudig 2000; Kindermann et al 2002).
Risks associated with pharmacologic 
treatment of BPSD
The elderly are at particular risk for drug-related adverse 
events. Older patients in general, and patients with dementia 
in particular, are more sensitive to medication adverse effects, 
including anticholinergic effects, orthostatic hypotension, 
sedation, parkinsonism, tardive dyskinesia (TD) and cog-
nitive impairment than younger patients with dementia or 
individuals without dementia. They are also especially prone 
to falls, and drugs that cause sedation, postural hypotension 
or extrapyramidal symptoms (EPS) have been found to cause 
an increased incidence of falls (Zaudig 2000).
The aging body undergoes physiological changes that 
affect both pharmacokinetics and pharmacodynamics (DeVane 
and Mintzer 2003). Aging is characterized by a progressive loss 
of the functional capacities of all the vital organs, including the 
brain. There is an alteration in the body’s composition of lean 
and fat body mass and a decrease in the excretory capacity of 
the kidney, causing many drugs to be eliminated from the body 
more slowly. Changes in drug distribution are also important. 
Age related reductions in liver mass, hepatic blood ﬂ  ow and 
hepatocyte function result in delayed clearance of drugs that 
are metabolized in the liver. Lower starting doses, smaller 
dose increments and longer dose escalation periods must be 
used to avoid potentially toxic drug accumulation. Concurrent 
illnesses and associated polypharmacy are extremely common 
in elderly patients. Potential drug-drug interactions must be 
considered (Zaudig 2000).
Central and peripheral anticholinergic adverse effects, 
such as constipation, urinary retention, dry mouth, blurred 
vision and cognitive deﬁ  cits, are particularly troublesome for 
elderly patients (Kindermann et al 2002). Peripheral effects 
include urinary retention, constipation, blurred vision, and 
dry mouth. Central anticholinergic effects include sedation, 
confusion, delirium, and cognitive decline. Elders are also 
more sensitive to the adverse effects related to blockade of 
adrenergic and histaminic receptors. Histaminic blockade 
causes sedation and adrenergic receptor blockade can lead 
to orthostatic hypotension, dizziness and syncope (which can 
contribute to falls) (DeVane and Mintzer 2003). Evidence 
also suggests that the relative afﬁ  nity at muscarinic and 
adrenergic receptors may affect multiple aspects of cognition, 
including memory and executive functions (Daniel 2000).Clinical Interventions in Aging 2007:2(4) 619
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An approach to management 
of BPSD
The initial approach to the management of BPSD should 
always include the non-pharmacologic therapies discussed 
earlier. Often, pharmacologic intervention is needed. As 
mentioned previously, there is no consensus nor clear stan-
dard of care when it comes to pharmacologic management 
of BPSD. We would like to offer, instead, general guidance 
for ﬁ  rst and second line treatment of some of the behavioral 
and psychological symptoms associated with dementia. 
Most patients with dementia present with more than one 
of these symptoms, and a single medication may be able to 
treat multiple symptoms. First, when the diagnosis of AD 
has been made, a cholinesterase inhibitor could be initiated, 
with or without memantine (in mild to moderate AD). For 
second line therapies, providers should use target symptoms 
to guide their treatment. The SSRI antidepressants citalopram 
and sertraline have the best evidence for their use in reducing 
symptoms such as irritability, sleep disturbances, and some 
aggression. Trazodone may also be helpful, particularly with 
sleep disturbances and agitation. Benzodiazepines can be 
effective but must be used with caution in the elderly. Finally, 
the atypical antipsychotics such as risperidone and olanzap-
ine may be used for controlling aggression, agitation and 
psychotic symptoms in many different forms of dementia. 
We caution, however, that close monitoring be undertaken, 
and the medications be carefully titrated for effect. If they 
are not effective in controlling target symptoms, then the 
medications should be discontinued.
Conclusion
The increasing life expectancy in most Western societies 
along with other factors such as improved detection of 
dementia, administration of disease modifying agents, and 
improved healthcare techniques, has led to a rapidly growing 
number of elderly people with dementia and longer survival 
of these patients. Behavioral and psychological disorders 
occur in most dementing conditions, usually in later stages. 
One half of these patients experience psychotic symptoms, 
such as delusions and hallucinations, which in turn makes 
them more vulnerable to severe agitation. Treatment of these 
disorders in dementia should reduce the patients’ and the care-
givers’ burden, resulting in lower rates of institutionalization 
and less psychophysical morbidity in the family (Stoppe et al 
1999; Kindermann et al 2002).
Caregiver education, support and behavioral training, 
and environmental modiﬁ  cations are important components 
of the management of BPSD, and should be the ﬁ  rst step 
in approaching the dementia patient with these symptoms. 
However, pharmacologic management is often needed. There 
are many classes of medications to choose from for treating 
these neuropsychiatric symptoms, but the evidence behind 
treatment is varied and confusing. Clinicians considering 
pharmacologic therapy, especially the antipsychotics, should 
discuss the potential risks and beneﬁ  ts of such therapy with 
patients and their surrogate decision makers, noting any risk 
factors those patients may have (for CV disease, for example). 
Good clinical practice dictates that patients receive individual-
ized pharmacotherapeutic dosing regimens initiated and modi-
ﬁ  ed relative to clinical efﬁ  cacy and tolerability and targeted 
to speciﬁ  c neuropsychiatric symptoms (Tariot, Profenno et al 
2004). “The art of drug treatment is to use the right drug for 
the right symptoms at the proper stage of the disease starting 
low and going slow (Gauthier 2005, p 857).”
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